AlphaFod is a Google DeepMind algorithm that will determine the structures of 200 million proteins.

AlphaFold - Protein Structure Database -Developed by DeepMind and EMBL-EBI

AlphaFod is a Google DeepMind algorithm that will determine the structures of 200 million proteins.

DeepMind's AlphaFold AI technology predicts a protein's 3D structure based on its amino acid sequence. It consistently produces accurate results comparable to experiments.

DeepMind and EMBL’s European Bioinformatics Institute (EMBL-EBI) have partnered to create AlphaFold DB to make these predictions freely available to the scientific community. The latest database release contains over 200 million entries, providing broad coverage of UniProt (the standard repository of protein sequences and annotations). We provide individual downloads for the human proteome and for the proteomes of 47 other key organisms important in research and global health. We also provide a download for the manually curated subset of UniProt (Swiss-Prot).

AlphaFod is the algorithm that discovered the structures of all known proteins and will be advancing research in the fight against degenerative illnesses. Understanding the three-dimensional structure is a long-term project among the scientific community that attempts to root out all of these faults. Scientists have only discovered 200,000 in 60 years, but with this technique, they will be able to accomplish so in a couple of days. With scientific development, it will be able to speed up degenerative illness research.

Demis Hassabis, a 45-year-old programming and neuroscience specialist, founded Deepmind, an artificial intelligence startup, in 2012. Based on the same platform AlphaFod make it possible to foresee what is best and most feasible to tackle particular difficulties and this will save time for scientists in terms of study. This Google technology will be provided for free to all scientists worldwide.

A group at the University of Oxford has already utilized the first AlphaFod samples to treat malaria and has put into practice the way the illness stops multiplying.  This might result in a vaccine and drugs to combat it in a few years. The advancement will even allow for cost savings by eliminating the need for expensive equipment to conduct molecular research.

Source -